Gain Therapeutics Preps Phase 2 Trial for Parkinson’s Drug After Positive Phase 1b Data
Event summary
- Gain Therapeutics will present Phase 1b data for GT-02287 at AD/PD 2026, showing CNS target engagement and early clinical improvements in Parkinson’s patients.
- The company submitted additional preclinical data to the FDA in March 2026 and expects a response in the coming weeks.
- Phase 2 trial initiation for GT-02287 is on track for Q3 2026, pending FDA approval.
- GT-02287 is an allosteric modulator targeting glucocerebrosidase (GCase) dysfunction in Parkinson’s disease.
The big picture
Gain Therapeutics is advancing one of the first potential disease-modifying therapies for Parkinson’s, targeting the underlying pathophysiology rather than just symptoms. The shift from symptomatic relief to disease modification represents a significant strategic opportunity in neurodegenerative disease treatment. Success in Phase 2 could position GT-02287 as a key player in addressing the unmet needs of Parkinson’s patients, particularly those with GBA1 mutations.
What we're watching
- Regulatory Approval
- Whether the FDA will clear GT-02287 for Phase 2 trials without further delays, given the recent data submission.
- Clinical Validation
- How the Phase 1b extension data and upcoming Phase 2 trial will validate GT-02287’s disease-modifying potential in Parkinson’s.
- Competitive Positioning
- The pace at which Gain Therapeutics can differentiate GT-02287 in a crowded Parkinson’s disease-modifying therapy landscape.
Our editorial coverage:
Related topics